



Research Article

Central Hemodynamic Parameters are Altered in Resistant Hypertensive Individuals

João Marcos de Menezes Zanatta, Fábio dos Santos Ricardi, Elizabeth do Espírito Santo Cestário, Tatiana Azevedo, Jéssica Rodrigues Uyemura, Luciana Neves Cosenso-Martin, Juan Carlos Yugar-Toledo, José Fernando Vilela-Martin*

Internal Medicine Department, State Medical School, Sao Jose do Rio Preto (FAMERP), Sao Paulo, Brazil

ARTICLE INFO

Article History

Received 30 November 2019
Accepted 30 November 2019

Keywords

Hypertension
resistant hypertension
sodium
arterial stiffness

ABSTRACT

Background: Systemic arterial hypertension (SAH) is one of the major risk factors related to the development of cardiovascular diseases (CVD). Sodium intake is linked to elevated blood pressure and can be estimated by 24-h urinary sodium excretion. The objective of this study was to correlate 24 h urinary sodium excretion, blood pressure and arterial stiffness (AS) parameters in hypertensive individuals.

Methods: We evaluated 53 patients who underwent in-office 24-h blood pressure tests and AS parameters using the Mobil-O-Graph® equipment. The patients were divided into controlled hypertensive and resistant hypertensive. Unpaired *t*-test was performed with significance at $p < 0.05$.

Results: Mean age was 64.32 years; weight 77.56 kg; height 1.61 m; and BMI of 29.68 kg/m². Resistant hypertensive patients (25 subjects) have systolic blood pressure (SBP) ($p < 0.0001$), diastolic blood pressure (DBP) ($p = 0.004$), 24 h SBP ($p < 0.0001$), 24 h DBP ($p = 0.002$), pulse pressure (PP) ($p < 0.0001$), central systolic blood pressure (cSBP) ($p = 0.0003$) and central diastolic blood pressure (cDBP) ($p = 0.021$) higher than controlled hypertensive patients (28 subjects).

Conclusion: Peripheral and central arterial pressures are higher in resistant hypertensive than in controlled hypertensive. Sodium excretion is unrelated to hemodynamic variables. Age is related to the elevation of central pressure and pulse wave velocity.

© 2019 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V. This is an open access article distributed under the CC BY-NC 4.0 license (<http://creativecommons.org/licenses/by-nc/4.0/>).

1. INTRODUCTION

Systemic Arterial Hypertension (SAH) is known to be one of the major risk factors responsible for the development of target organ damage, such as heart, brain and kidneys, culminating in the main known Cardiovascular Diseases (CVD), including Acute Myocardial Infarction (AMI), Cerebrovascular Accident (CVA) and Chronic Kidney Disease (CKD), respectively [1]. It is also known that the prevalence of SAH in the world is in both developed and developing countries, and it is on the increase in the latter [2].

It is estimated that there are around 1.4 billion hypertensive people in the world [3], with 45 million in Brazil alone [4]. Considering this high prevalence and also taking into account the chronicity of the disease, studies that target clinical therapies for outcomes in which morbidity and mortality are decreasing and patients can live with a higher quality of life are needed.

Among the strategies for control of Blood Pressure (BP) by non-medical means, we found the reduction of sodium intake as one of the strategies. It has been found that hypertensive patients who decrease

their salt intake reduce up to 5.5 mmHg of their Systolic Blood Pressure (SBP) and 2.9 mmHg of Diastolic Blood Pressure (DBP) [5].

This effect is due to the involvement of sodium in the increase of Cardiac Output (CO) and Peripheral Vascular Resistance (PVR). Increased CO occurs due to the retention volume that sodium provides, as the kidneys cannot support excreting excess ingested sodium. This leads to increased plasma volume, preload and CO [6]. Elevation of PVR, in turn, is related to complex mechanisms involving changes in the secretory properties of vascular smooth muscle cells [7]. Such mechanisms seem to be associated with the pro-fibrotic effect of Transforming Growth Factor β -1 (TGF β -1) and the reduction of Nitric Oxide (NO) bioavailability, which promote decreased vascular compliance and vasoconstriction [8].

An indirect way of estimating sodium intake is by analyzing the 24-h urinary sodium (Na^+ U 24 h) test, since about 95% of ingested sodium is excreted [9]. Thus, Na^+ U 24 h is very useful for analyses that relate salt consumption with arterial hypertension parameters.

To evaluate the hypertensive patient, we can use mechanisms that go beyond the measurement of brachial BP in the office. A 24-h Ambulatory Blood Pressure Monitoring (24 h ABPM) provides us with critical data for diagnosis and follow-up, as well as informing us of central BP values and parameters related to arterial stiffness (AS) such as Pulse Wave Velocity (PWV) and Augmentation Index (AI) [3,10]. All these data make it possible for the physician to proceed in his conduct with more precision

*Corresponding author. Email: vilelamartin@uol.com.br

Peer review under responsibility of the Association for Research into Arterial Structure and Physiology

Data availability statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

and safety, knowing several unusual indicators for patient evaluation. Central BP, for example, has been shown to be important for directing antihypertensive therapy, as it more reliably expresses changes related to arterial stiffness and is a better predictor of cardiovascular mortality [11,12].

The objective of this study was to correlate Na^+ U 24 h excretion with blood pressure and various arterial stiffness parameters, such as central arterial pressure, PWV and augmentation index, in individuals with controlled or resistant systemic arterial hypertension.

2. MATERIALS AND METHODS

Cross-sectional study was performed at the Hypertension Outpatient Clinic of the São José do Rio Preto Medical School - FAMERP, São Paulo State, Brazil. The sample, consisting of 53 patients, was randomly constructed, according to the appointment schedule of the mentioned service. All participants were informed about their involvement with the study and signed the Informed Consent Form (ICF) approved by the institution's Research Ethics Committee.

Patients who participated were over 18 years, diagnosed with hypertension for at least 4 weeks, regularly enrolled in the service mentioned above. Patients who met at least one of the following criteria were excluded from the study: renal failure on dialysis program, hospitalization within the last 60 days before enrollment, hemodynamic instability requiring vasoactive drugs within 30 days prior to inclusion, heart failure with functional class III or IV, pregnancy/breastfeeding, severe liver disease, people with HIV, psychiatric disorders that prevented compliance with the protocol, stroke or AMI within 30 days prior to inclusion, severe diseases and/or cancer with a prognosis of <1 year.

Through the analysis of electronic medical records, the following data were collected: Na^+ U 24 h, peripheral blood pressure measured in the office and antihypertensive drugs used by patients, in addition to confirming anthropometric data such as age, gender, weight, height and Body Mass Index (BMI).

Values related to peripheral blood pressure, central blood pressure and other parameters of arterial stiffness, such as PWV and augmentation index, were obtained through 24 h ABPM, with the Mobil-O-Graph® equipment (version 12, 2000, UK) according to the manufacturer's instructions. Such technique increasingly becomes clinically available as a noninvasive mechanism for central pressure assessment [2].

Participants were divided into two groups: "controlled hypertensive" and "resistant hypertensive", which was made based on analysis of the medications and blood pressure values obtained in this study, and their indicators were compared.

Descriptive analysis of quantitative variables was performed with values presented as mean and standard deviation. For comparison of central blood pressure behavior, unpaired *t*-test was performed in the Controlled Hypertensive and Resistant Hypertensive groups. To evaluate the correlation between Na^+ U 24 h excretion and central arterial pressure, Pearson's correlation coefficient was used. Multivariate analysis of central pressure behavior was also performed in each study group.

All statistical analyses were performed using the Sigma-Stat Statistical Software program and Graph-Pad In Stat version 5.0 (Systat Software Inc., California, USA). Sample size was estimated based on a test power of 80% and significance level of $p < 0.05$.

3. RESULTS

Of the 53 participants in this study, 28 were classified in the controlled hypertensive group and 25 in the resistant hypertensive group. The average age of the sample as a whole was 64.32 years; weight 77.56 kg; height 1.61 m; and BMI of 29.68 kg/m².

The general characteristics, hemodynamic characteristics such as 24 h SBP, 24 h DBP, Pulse Pressure (PP), central SBP (cSBP), central DBP (cDBP) and PWV - corresponding values of Mobil-O-Graph® - analysis and Na^+ U 24 h excretion rate are presented in Table 1, divided into controlled and resistant hypertensive groups. Some statistical differences between the groups are shown in Figure 1.

Table 1 | General and hemodynamic characteristics of the study population

Data	Controlled hypertensive (N = 28)	Resistant hypertensive (N = 25)	<i>p</i>
Age (years)	64.107 ± 10.3435	64.560 ± 12.8390	0.889
Weight (kg)	78.804 ± 13.1257	76.164 ± 19.3691	0.569
Height (m)	1.630 ± 0.09014	1.595 ± 0.1052	0.204
BMI (kg/m ²)	29.675 ± 4.6009	29.694 ± 6.1557	0.989
SBP (mmHg)	123.929 ± 9.5914	157.760 ± 19.4064	<0.0001
DBP (mmHg)	74.321 ± 8.0326	84.640 ± 14.9328	0.004
Heart rate HR (bpm)	73.750 ± 8.6864	70.120 ± 7.8226	0.115
SBP 24 h (mmHg)	114.107 ± 8.0615	128.000 ± 12.9422	<0.0001
DBP 24 h (mmHg)	71.500 ± 5.7639	74.720 ± 10.4782	0.002
PP (mmHg)	42.607 ± 7.4850	53.120 ± 8.1359	<0.0001
cSBP (mmHg)	105.964 ± 7.4956	118.000 ± 13.6961	0.0003
cDBP (mmHg)	72.571 ± 6.0150	76.000 ± 10.6105	0.021
PWV (m/s)	8.914 ± 1.5818	9.444 ± 1.9935	0.105
Na^+ U 24 h (mEq/L)	170.643 ± 83.9057	158.280 ± 64.1317	0.553

Mean ± standard deviation for all data presented.

The Na⁺ U 24 h excretion did not correlate with hemodynamic changes in both groups.

Multivariate analysis of the controlled hypertensive group for PWV (measured by Mobil-O-Graph) and SBP, DBP, cSBP, cDBP, Age, BMI, and Na⁺ U 24 h showed an association of PWV with SBP ($p = 0.0229$) and age ($p < 0.0001$). Results are presented in Table 2.

Multivariate analysis of the controlled hypertensive group for augmentation index (measured by Mobil-O-Graph) and SBP, DBP, cSBP, cDBP, age, BMI and Na⁺ U 24 h showed association of augmentation index with SBP ($p = 0.0466$), DBP ($p = 0.0175$) and office DBP ($p = 0.0230$). Results are presented in Table 3.

Multivariate analysis of the resistant hypertensive group for PWV (measured by Mobil-O-Graph) and SBP, DBP, age, BMI and Na⁺ U




Figure 1 | Comparison between Controlled Hypertensive (C) and Resistant/Non-controlled (NC) groups. NS, not significant.

Table 2 | Multivariate analysis of controlled hypertensive for PWV (measured by Mobil-O-Graph) and SBP, DBP, cSBP, cDBP, Age, BMI and Na⁺ U 24 h

Independent variables	β coefficient	Standard deviation	p
SBP	-0.0008421	0.007827	0.9154
DBP	-0.02198	0.01326	0.1128
cSBP (Mobil-O-Graph)	0.03246	0.01317	0.0229*
cDBP (Mobil-O-Graph)	0.02248	0.01872	0.2437
Age	0.1096	0.03849	<0.0001*
BMI	0.2066	0.06963	0.4116
Na ⁺ U 24 h	-0.002360	0.004066	0.6576

* $p < 0.05$.

Table 3 | Multivariate analysis of controlled hypertensive for augmentation index (measured by Mobil-O-Graph) and SBP, DBP, cSBP, cDBP, age, BMI and Na⁺ U 24 h

Independent variables	β coefficient	Standard deviation	p
SBP	-0.01603	0.1533	0.9178
DBP	0.06611	0.2685	0.0230*
cSBP (Mobil-O-Graph)	0.4882	0.2302	0.0466*
cDBP (Mobil-O-Graph)	-0.9526	0.3677	0.0175*
Age	-0.07417	0.1705	0.6682
BMI	-0.2784	0.3078	0.3765
Na ⁺ U 24 h	-0.007094	0.01843	0.9178

* $p < 0.05$.

Table 4 | Multivariate analysis of resistant hypertensive for PWV (as measured by Mobil-O-Graph) and cSBP, cDBP, age, BMI and Na⁺ U 24 h

Independent variables	β coefficient	Standard deviation	p
cSBP (Mobil-O-Graph)	0.03061	0.009436	0.0043*
cDBP (Mobil-O-Graph)	0.00003800	0.01272	0.9976
Age	0.1527	0.006513	<0.0001*
BMI	-0.02009	0.01263	0.1282
Na ⁺ U 24 h	0.0001081	0.001250	0.9320

* $p < 0.05$.

Table 5 | Multivariate analysis of resistant hypertensive for augmentation index (measured with Mobil-O-Graph) and SBP, DBP, cSBP, cDBP, age, BMI and Na⁺ U 24 h

Independent variables	β coefficient	Standard deviation	p
SBP	0.1008	0.1326	0.4574
DBP	-0.1484	0.1908	0.4472
cSBP (Mobil-O-Graph)	0.6080	0.2427	0.0227*
cDBP (Mobil-O-Graph)	-0.3408	0.3279	0.3132
Age	0.2221	0.1990	0.2800
BMI	0.005054	0.3275	0.9879
Na ⁺ U 24 h	-0.01868	0.03167	0.5631

* $p < 0.05$.

24 h showed an association of PWV with SBP ($p = 0.0043$) and age ($p < 0.0001$). Results are presented in Table 4.

Multivariate analysis of the resistant hypertension group for augmentation index (measured by Mobil-O-Graph) and SBP, DBP, cSBP, cDBP, age, BMI and Na⁺ U 24 h showed association of augmentation index with cSBP ($p = 0.0227$). The results are presented in Table 5.

4. DISCUSSION

Central systolic pressure is an important predictor of cardiovascular risk; arterial properties that determine central systolic pressure values and peripheral blood pressure amplification are modulated by age, cardiovascular risk factors, drugs, and vasoactive substances. Elevated Na⁺ U 24 h excretion correlates with hemodynamic and structural changes in the vascular wall.

Analyzing the results of this study, it was possible to observe that, among the general characteristics, SBP and DBP (both office measurements) are higher in the resistant hypertensive group. Among the hemodynamic variables, 24 h SBP, 24 h DBP, PP, cSBP and cDBP were also statistically higher in the resistant hypertensive group. These findings reflect the direct relationship between being a patient resistant to antihypertensive treatment and having higher blood pressure and stiffness.

These findings are corroborated by the results of the study by Chung et al. [13], who worked with 1620 hypertensive patients. The means of anthropometric variables, age and BMI are similar to those of the present study. They concluded that the degree of arterial stiffness and SBP alone are higher in resistant hypertensive patients compared with controlled hypertensive patients.

Another study that also presented results that support those found in the present study was conducted by Mendes [14], who concluded that resistant hypertensive individuals have higher levels of

peripheral and central blood pressure than controlled hypertensive individuals.

We can highlight at this time, the average medications for blood pressure control used in each group of this study. Controlled hypertensive used on average, 2.89 antihypertensives; while resistant hypertensive used 3.44 antihypertensives. We realized that more medication is needed in order to lower blood pressure in resistant hypertensive patients, which is often a frustrated attempt.

Although PWV did not present a statistically significant difference between the two groups, its mean was higher in resistant hypertensive individuals, indicating that arterial stiffness increases blood velocity and contributes to possible target organ damage. The study by Mendes presented the same results, that is, a higher mean PWV in resistant hypertensive than in controlled hypertensive, but not statistically significant [14].

Chung et al. [13], in turn, found significantly that PWV is higher in resistant hypertensive individuals, confirming the trend observed in the present study. Lotufo et al. [15], in the first Brazilian study that analyzed the prevalence of resistant hypertension in the country, also presented results similar to those of Chung et al. when analyzing PWV comparing controlled and resistant hypertensive patients.

Regarding Na^+ U 24 h excretion, we found higher values in the controlled hypertensive group than in the resistant hypertensive group. We believe this was due to the need for resistant patients to better control their sodium intake as part of their non-drug treatment. Also, because of the importance of their condition, these patients are more often advised by healthcare professionals to reduce their intake of high-salt foods. Boutari et al. [16] demonstrated that 91% of resistant hypertensive patients received clear instructions on the harmful effects of salt intake to control blood pressure and 76% of these reduced consumption.

By performing multivariate analysis, a direct relationship of PWV with cSBP and age was observed in the controlled hypertensive group and with SBP and age in the resistant hypertensive group. With these data, we found that PWV tends to increase with increasing cSBP and SBP, as well as with the patient's age. This finding was also reported by Chung et al. [13], regarding SBP, who concluded that PWV is directly related to blood pressure levels. Regarding the relationship of PWV with the patient's age, Díaz et al. [17] confirmed their increasing behavior according to aging, about 6–8% every decade of life, highlighting a more significant increase after 50 years. Meyer et al. [18], in a study with 4974 patients, also found a direct association between PWV and age.

Also by multivariate analysis, there was a direct relationship between AI and DBP, cSBP and cDBP, in the controlled hypertensive group, and with cSBP, in the RESISTANT HYPERTENSIVE group. Thus, AI should be higher as DBP, cSBP and cDBP increase. Terentes-Printzios et al. [19] also demonstrated that AI is directly related to increased cardiovascular risk. The study by Totaro et al. [20] also showed a relationship between AI and cBP, reaffirming the findings of the present study.

It is noteworthy that there was no statistically significant difference between the groups regarding age, height, weight and BMI, which represents the homogeneity of the population sample studied.

It is worth noting that the main limitation of this study concerns the number of patients studied. We believe that more statis-

tically significant comparisons could have been found if the sample were larger.

5. CONCLUSION

Peripheral blood pressure, central blood pressure, and pulse pressure are higher in resistant hypertensive patients than in controlled hypertensive patients.

The mean PWV was also higher in resistant hypertensive patients, although this result was not statistically significant. The Na^+ U 24 h excretion did not correlate with hemodynamic changes in both groups studied.

Age is the main independent variable associated with increased central blood pressure and PWV in both controlled and resistant hypertensive patients. Augmentation index is directly related to central blood pressure. Further studies with larger sample size are needed to confirm the results.

CONFLICTS OF INTEREST

The author declare they have no conflicts of interest.

AUTHORS' CONTRIBUTION

JMMZ and FSR contributed in the study design, data collection and performed the writing. EESC, TA and JRU contributed in the data collection. LNCM participated in the data analysis and review. JCYT performed the statistical analysis and review. JFVM contributed in the study design, coordination, and data analysis and helped to draft the manuscript.

FUNDING

This work was supported by the National Council for Scientific and Technological Development (CNPq), a body belonging to the Federal Government of Brazil. There was no effective involvement of the above mentioned entity in the preparation of this work.

ACADEMIC LINK

This study is linked to the postgraduate program of the School of Medicine of São José do Rio Preto, Sao Paulo, Brazil.

ACKNOWLEDGMENTS

The authors would like to specially thank each of the patients who freely accepted to participate in this study, giving their time for data collection and thus contributing to the enrichment of science.

REFERENCES

- [1] Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial

- hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J* 2018; 39:3021–104.
- [2] Salem H, Hasan DM, Eameash A, El-Mageed HA, Hasan S, Ali R. Worldwide prevalence of hypertension: a pooled meta-analysis of 1670 studies in 71 countries with 29.5 million participants. *J Am Coll Cardiol* 2018;71:A1819.
- [3] Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation* 2016;134:441–50.
- [4] Malachias MVB, Souza WKS, Plavnik FL, Rodrigues CIS, Brandão AA, Neves MFT, et al. 7th Brazilian Guideline of arterial hypertension. *Arq Bras Cardiol* 2016;107:1–83.
- [5] Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. *Cochrane Database Syst Rev* 2017;4:CD004022.
- [6] Nobre F, Coelho EB, Lopes PC, Geleilete TJM. Primary systemic arterial hypertension. *Medicina (Ribeirão Preto)* 2013;46:256–72.
- [7] Safar ME, Thuilliez C, Richard V, Benetos A. Pressure-independent contribution of sodium to large artery structure and function in hypertension. *Cardiovasc Res* 2000;46:269–76.
- [8] Sanders PW. Vascular consequences of dietary salt intake. *Am J Physiol Renal Physiol* 2009;297:F237–F43.
- [9] Polónia J, Maldonado J, Ramos R, Bertoquini S, Duro M, Almeida C, et al. Estimation of salt intake by urinary sodium excretion in a Portuguese adult population and its relationship to arterial stiffness. *Rev Port Cardiol* 2006;25:801–17 [Article in English, Portuguese].
- [10] Santiago LM, Simões AR, Ricardo Miranda P, Matias C, Rosendo I, Constantino L, et al. Peripheral blood pressure by Dinamap and central blood pressure by applanation tonometry in outpatient general practice. *Rev Port Cardiol* 2013;32:497–503.
- [11] Fernandes LAB. Effect of a diuretic or angiotensin II receptor blocker on central blood pressure in patients with prehypertension and stage 1 hypertension [dissertation]. São José do Rio Preto: Faculty of Medicine of São José do Rio Preto; 2015.
- [12] Eguchi K, Miyashita H, Shimada K, ABC-J II investigators. Is high central BP but normal office brachial BP a risk?—The ABC-J II Study. *Vasc Fail* 2018;2:66–73.
- [13] Chung CM, Cheng HW, Chang JJ, Lin YS, Hsiao JF, Chang ST, et al. Relationship between resistant hypertension and arterial stiffness assessed by brachial-ankle pulse wave velocity in the older patient. *Clin Interv Aging* 2014;9:1495–502.
- [14] Mendes ABB. Evaluation of arterial stiffness and central aortic pressure in resistant hypertensive patients [dissertation]. São José do Rio Preto: Faculty of Medicine of São José do Rio Preto; 2015.
- [15] Lotufo PA, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults—the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). *J Clin Hypertens (Greenwich)* 2015;17:74–80.
- [16] Boutari C, Stavropoulos K, Imprialos KP, Kokkinos P, Pittaras A, Faselis C, et al. Evaluation of sodium intake in patients with resistant hypertension: clinical practice in Greece. *J Hypertens* 2016;34:e175.
- [17] Díaz A, Galli C, Tringler M, Ramírez A, Cabrera Fischer EI. Reference values of pulse wave velocity in healthy people from an urban and rural Argentinean population. *Int J Hypertens* 2014;2014:653239.
- [18] Meyer ML, Tanaka H, Palta P, Cheng S, Gouskova N, Aguilar D, et al. Correlates of segmental pulse wave velocity in older adults: the Atherosclerosis Risk in Communities (ARIC) study. *Am J Hypertens* 2015;29:114–22.
- [19] Terentes-Printzios D, Vlachopoulos C, Xaplanteris P, Ioakeimidis N, Aznaouridis K, Baou K, et al. Cardiovascular risk factors accelerate progression of vascular aging in the general population: results from the CRAVE study (Cardiovascular Risk Factors Affecting Vascular Age). *Hypertension* 2017;70:1057–64.
- [20] Totaro S, Khoury PR, Kimball TR, Dolan LM, Urbina EM. Arterial stiffness is increased in young normotensive subjects with high central blood pressure. *J Am Soc Hypertens* 2015;9:285–92.

Intentionally Left Blank